Functional and binding characterizations of urotensin II-related peptides in human and rat urotensin II-receptor assay

Journal of Pharmacology and Experimental Therapeutics

Volumn 306, Issue 3, 2003, Pages 1200-1209

  Brkovic, Alexandre ^a   Hattenberger, Almut ^b   Kostenis, Evi ^b,d   Klabunde, Thomas ^b   Flohr, Stefanie ^b,c   Kurz, Michael ^b   Bourgault, Steve ^a   Fournier, Alain ^a,e  

^a INRS INSTITUT ARMAND FRAPPIER   (Canada)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^c 7TM Pharma ^*  (Denmark)

^d NOVARTIS PHARMA AG   (Switzerland)

^e INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; UROTENSIN II; VALINE;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BIOASSAY; CALCIUM MOBILIZATION; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; DISULFIDE BOND; DRUG ACTIVITY; DRUG BINDING; DRUG DETERMINATION; DRUG POTENCY; DRUG STRUCTURE; HOMEOSTASIS; MEMBRANE BINDING; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; STRUCTURE ACTIVITY RELATION; THORACIC AORTA; VASOCONSTRICTION;

ANIMALS; AORTA; BINDING SITES; CALCIUM; HUMANS; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CELL SURFACE; RECEPTORS, G-PROTEIN-COUPLED; SPECIES SPECIFICITY; UROTENSINS; VASOCONSTRICTION;

EID: 0041430625     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.052415     Document Type: Article

References (34)

1. Ames RS, Sarau HM, Chambers JK, Willette RN, Alyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Coatney RW, et al. (1999) Human urotensin II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature (Lond) 401:282-286.
2. Böhm F and Pernow J (2002) Urotensin II evokes potent vasoconstriction in humans in vivo. Br J Pharmacol 135:25-27.
3. Camarda V, Guerrini R, Kostenis E, Rizzi A, Calò G, Hattenberger, Zucchini M, Salvadori S, and Regoli D (2002) A new ligand for the urotensin II receptor. Br J Pharmacol 137:311-314.
4. Chou PY and Fasman GD (1978) Empirical predictions of protein conformation. Annu Rev Biochem 47:251-276.
5. Conlon JM (2000) Singular contributions of fish neuroendocrinology to mammalian regulatory peptide research. Regul Pept 93:3-12.
6. Coulouarn Y, Lihrmann I, Jegou S, Anouar Y, Tostivint H, Beauvillain JC, Conlon JM, Bern HA, and Vaudry H (1998) Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci 95:15803-15808.
7. Coy DH, Rossowski WJ, Cheng BL, Hocart SJ, and Taylor JE (2000) Novel urotensin II (UII) antagonists point to multiple receptor involvement in UII bioactivity (Abstract). Regul Pept 94:48.
8. Douglas SA, Ashton DJ, Sauermelch CF, Coatney RW, Ohlstein DH, Ruffolo MR, Ohlstein EH, Aiyar NY, and Willette RN (2000b) Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primate. J Cardiovasc Pharmacol 26:163-166.
9. Douglas SA, Sulpizio AC, Piercy V, Sarau HM, Ames RS, Aiyar NV, Ohlstein EH, and Willette RN (2000a) Differential vasoconstrictor activity of human urotensin II in vascular tissue isolated from rat, mouse, dog, marmoset and cynomolgus monkey. Br J Pharmacol 131:1262-1274.
10. Flohr S, Kurz M, Kostenis E, Brkovic A, Fournier A, and Klabunde T (2002) Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. J Med Chem 45:1799-1805.
11. Freidinger RM, Perlow DS, Randall WC, Saperstein R, Arison BH, and Veber DF (1984) Conformational modifications of cyclic hexapeptide somatostatin analogs. Int J Pept Protein Res 23:142-150.
12. Grieco P, Carotenuto A, Patacchini R, Maggi CA, Novellino E, and Rovero P (2002) Design, synthesis and conformational analysis and biological studies of urotensin II lactam analogues. Bioorg Med Chem 10:3731-3739.
13. Grieco P, Patacchini R, Carotenuto A, Maggi CA, Novellino E, and Rovero P (2001) Design, synthesis and conformational analysis of human urotensin II (U-II) analogues with lactam bridge, in Peptides: The Wave of the Future (Lebl M and Houghten RA eds) pp 630-631, American Peptide Society, San Diego and Kluwer Academic Publishers, The Netherlands.
14. Hillier C, Berry C, Petrie MC, O'Dwyer PJ, Hamilton C, Brown A, and McMurray J (2001) Effects of urotensin II in human arteries and veins of varying caliber. Circulation 103:1378-1381.
15. Itoh H, Itoh Y, Rivier J, and Lederis K (1987) Contraction of the major artery segments of the rat by fish neuropeptide urotensin II. Am J Physiol 252:361-366.
16. Janecka A, Zubrzycka M, and Janecki T (2001) Somatostatin anlogs. J Peptide Res 58:91-107.
17. Kenakin TP (2002) Drug efficacy at G protein-coupled receptors. Annu Rev Pharmacol Toxicol 42:349-379.
18. Kenakin TP and Beek D (1984) Relative efficacy of prenalterol and pirbuterol for β1 adrenoceptors: measurement of agonist affinity by alteration of receptor number. J Pharmacol Exp Ther 229:340-345.
19. Kinney WA, Almond HR Jr, Maryanoff BE, Qi J, Smith CE, Santulli RJ, de Garavilla L, Andrade-Gordon P, Cho DS, Everson AM, et al. (2001) Structure-function study of the urotensin-II peptide: Elucidation of features required for potent agonist activity, 222nd American Chemical Society National Meeting, Abstract 232, 28 August, 2001, Chicago.
20. Kinney WA, Almond HR Jr, Qi J, Smith CE, Santulli RJ, de Garavilla L, Andrade-Gordon P, Cho DS, Everson AM, Feinstein MA, et al. (2002) Structure-function analysis ofurotensin II and its use in the construction of a ligand-receptor working model. Angew Chem Int Edit 41:2940-2944.
21. Maguire JJ, Kuc RE, and Davenport AP (2000) Orphan-receptor ligand human urotensin II: receptor localization on human tissues and comparison of the vasoconstrictor responses with endothelin-1. Br J Pharmacol 131:441-446.
22. Manning M, Stoev S, Cheng LL, Wo NC, and Chan WY (1999) Synthesis and structure-activity investigation of novel vasopressin hypotensive peptide agonists. J Pept Sci 5:472-490.
23. Marchese A, Heiber M, Nguyen T, Heng HHQ, Saldivia VR, Cheng R, Murphy PM, Tsui L-C, Shi X, Gregor P, et al. (1995) Cloning and chromosomal mapping of three novel genes, GPR9, GPR10, and GPR14, encoding receptors related to interleukin 8, neuropeptide Y, and somatostatin receptors. Genomics 29:335-344.
24. Paysant J, Rupin A, Simonet S, Fabiani JN, and Verbeuren TJ (2001) Comparison of the contractile responses of human coronary bypass grafts and monkey arteries to human urotensin-II. Fundam Clin Pharmacol 15:227-231.
25. Pearson D, Shively JE, Clark BR, Geschwind IL, Barkley M, Nishioka RS, and Bern HA (1980) Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. Proc Natl Acad Sci 77:5021-5024.
26. Perkins TD, Bansal S, and Barlow DJ (1990) Molecular modelling and design of analogues of the peptide hormone urotensin II. Biochem Soc Trans 18:918-919.
27. Rizzi A, Rizzi C, Amadesi S, Calo G, Varani K, Inamura N, and Regoli D (1999) Pharmacological characterization of the first nonpeptide bradykinin B2 receptor agonist FR190997: an in vitro study on human, rabbit and pig vascular B2 receptors. Naunyn Schiedeberg's Arch Pharmacol 360:361-367.
28. Rohrer SP, Birzin ET, Mosley RT, Berk SC, Hutchins SM, Shen D-M, Xiong Y, Hayes EC, Parmar RM, Foor F, et al. (1998) Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science (Wash DC) 282:737-740.
29. Rossowski WJ, Cheng BL, Taylor JE, Datta R, and Coy DH (2002) Human urotensin II-induced aorta contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists. Eur J Pharmacol 438:159-170
30. Russell FD, Molenaar P, and O'Brien DM (2001) Cardiostimulant effects of urotensin-II in human heart in vitro. Br J Pharmacol 132:5-9.
31. Stirrat A, Gallagher M, Douglas SA, Ohlstein EH, Berry C, Kirk A, Richardson M, and MacLean MR (2001) Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am J Physiol Heart Circ Physiol 280:H925-H928.
32. Strnad J and Hadcock JR (1995) Identification of a critical aspartate residue in transmembrane domain three necessary for the binding of somatostatin to the somatostatin receptor SSTR2. Biochem Biophys Res Commun 216:913-921.
33. Watanabe T, Pakala R, Katagiri T, and Benedict CR (2001) Synergistic effect of urotensin II with serotonin on vascular smooth muscle cell proliferation. J Hypertens 19:2191-2196.
34. Wilkinson IB, Affolter JT, de Haas SL, Pellegrini MP, Boyd J, Winter MJ, Balment RJ, and Webb DJ (2002) High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. Cardiovasc Res 53:341-347.